<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B9721CD9-D357-473F-88D0-8BBA65351B1F"><gtr:id>B9721CD9-D357-473F-88D0-8BBA65351B1F</gtr:id><gtr:name>University of Pecs</gtr:name><gtr:address><gtr:line1>University of Pecs</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CE3426C5-5648-4E15-8E8A-EABE25F49E3A"><gtr:id>CE3426C5-5648-4E15-8E8A-EABE25F49E3A</gtr:id><gtr:name>Pharmnovo AB/Pharmnovo UK Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77C66895-4D42-4105-A4C9-46E246CA4A4B"><gtr:id>77C66895-4D42-4105-A4C9-46E246CA4A4B</gtr:id><gtr:name>University of Auckland</gtr:name><gtr:address><gtr:line1>The University of Auckland</gtr:line1><gtr:line2>Private Bag 92601</gtr:line2><gtr:line3>Symonds Street</gtr:line3><gtr:line4>Auckland</gtr:line4><gtr:postCode>1150</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A"><gtr:id>5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A</gtr:id><gtr:name>Aston University</gtr:name><gtr:address><gtr:line1>Aston Triangle</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:postCode>B4 7ET</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0C8A61C0-41B2-4A21-B0DB-08F235F18F0B"><gtr:id>0C8A61C0-41B2-4A21-B0DB-08F235F18F0B</gtr:id><gtr:name>Uni of South Bohemia Ceske Budejovice</gtr:name><gtr:address><gtr:line1>University Ceske Budejovice</gtr:line1><gtr:line2>Branisovska 31</gtr:line2><gtr:postCode>CZ-37005</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7238F003-CBF7-48C6-9263-5FB285CF9651"><gtr:id>7238F003-CBF7-48C6-9263-5FB285CF9651</gtr:id><gtr:name>OnTarget Chemistry</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ED6A6B32-663C-4A62-A33B-2C6A68E2E102"><gtr:id>ED6A6B32-663C-4A62-A33B-2C6A68E2E102</gtr:id><gtr:name>University of Essex</gtr:name><gtr:department>Biological Sciences</gtr:department><gtr:address><gtr:line1>Wivenhoe Park</gtr:line1><gtr:line4>Colchester</gtr:line4><gtr:line5>Essex</gtr:line5><gtr:postCode>CO4 3SQ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ED6A6B32-663C-4A62-A33B-2C6A68E2E102"><gtr:id>ED6A6B32-663C-4A62-A33B-2C6A68E2E102</gtr:id><gtr:name>University of Essex</gtr:name><gtr:address><gtr:line1>Wivenhoe Park</gtr:line1><gtr:line4>Colchester</gtr:line4><gtr:line5>Essex</gtr:line5><gtr:postCode>CO4 3SQ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B9721CD9-D357-473F-88D0-8BBA65351B1F"><gtr:id>B9721CD9-D357-473F-88D0-8BBA65351B1F</gtr:id><gtr:name>University of Pecs</gtr:name><gtr:address><gtr:line1>University of Pecs</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CE3426C5-5648-4E15-8E8A-EABE25F49E3A"><gtr:id>CE3426C5-5648-4E15-8E8A-EABE25F49E3A</gtr:id><gtr:name>Pharmnovo AB/Pharmnovo UK Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77C66895-4D42-4105-A4C9-46E246CA4A4B"><gtr:id>77C66895-4D42-4105-A4C9-46E246CA4A4B</gtr:id><gtr:name>University of Auckland</gtr:name><gtr:address><gtr:line1>The University of Auckland</gtr:line1><gtr:line2>Private Bag 92601</gtr:line2><gtr:line3>Symonds Street</gtr:line3><gtr:line4>Auckland</gtr:line4><gtr:postCode>1150</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A"><gtr:id>5BFB9036-9D16-4AB9-A9EF-097BB6FBD69A</gtr:id><gtr:name>Aston University</gtr:name><gtr:address><gtr:line1>Aston Triangle</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:postCode>B4 7ET</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0C8A61C0-41B2-4A21-B0DB-08F235F18F0B"><gtr:id>0C8A61C0-41B2-4A21-B0DB-08F235F18F0B</gtr:id><gtr:name>Uni of South Bohemia Ceske Budejovice</gtr:name><gtr:address><gtr:line1>University Ceske Budejovice</gtr:line1><gtr:line2>Branisovska 31</gtr:line2><gtr:postCode>CZ-37005</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F649AB83-DC92-4360-807F-BBFEF0DE8EE4"><gtr:id>F649AB83-DC92-4360-807F-BBFEF0DE8EE4</gtr:id><gtr:name>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7238F003-CBF7-48C6-9263-5FB285CF9651"><gtr:id>7238F003-CBF7-48C6-9263-5FB285CF9651</gtr:id><gtr:name>OnTarget Chemistry</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9E8CF8A8-2E28-4C49-A9C2-D3BE2FC339A5"><gtr:id>9E8CF8A8-2E28-4C49-A9C2-D3BE2FC339A5</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Wall</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A5BC8C8E-8FA9-4534-BFE1-1CA4E013809C"><gtr:id>A5BC8C8E-8FA9-4534-BFE1-1CA4E013809C</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Arthur</gtr:otherNames><gtr:surname>Reynolds</gtr:surname><gtr:orcidId>0000-0001-9267-5141</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001812"><gtr:id>03E13776-A20F-4518-8F35-8505786551F0</gtr:id><gtr:title>Development and application of QM/MM calculations for fragment-based drug design</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1001812</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Fragment-based drug design, FBDD, is a highly promising novel approach for

identifying lead compounds in a drug development programme10. It therefore lies

firmly within one of the 10 MRC-identified health research opportunities for focusing

strategic research, namely ?Development of new interventions?. FBDD offers efficient

screening of chemical space so that higher hit rates are obtained in the initial phases

and through careful attention to molecular properties the resulting drug candidates

should have less chance of failure later in the process. However, FBDD also poses

difficult biophysical and structural problems that need to be addressed, hence the

strategic need for this proposal. The academic partner has current BBSRC funding to

develop quantum mechanics (QM) based QM/MM methods that include molecular

mechanics (MM) polarization. He has plans for other significant improvements to

correctly address the steric repulsion between drug and enzyme using exponential

repulsion (which is essential for success in crystal structure prediction11) rather than

the computationally expedient r-12 repulsion. The industrial partner has a strong

development interest in FBDD and is interested in using QM/MM to address the

structural demands of FBDD since current docking methods are unreliable and the

interpretation of X-ray structures of bound fragments can be ambiguous. The

interchange enabled by this programme, will not only result in the development of

new tools to underpin basic FBDD research, but also offers the potential to impact

industrial and academic scientists in both institutions. Specific research goals include

(i) a thorough survey of the usefulness of QM/MM in virtual screening. (ii) An analysis

of the best way in which QM/MM with MM polarization can be used in virtual

screening. (iii) An investigation of the use of realistic repulsion in virtual screening.

(iv) An investigation in the use of QM/MM, in combination with the proposed

improvements, in interpreting ambiguous X-ray crystal structures. The applicants

have shared research goals as the industrial partner is interested in being able to

apply efficient software to FBDD while the academic partner is interested in

developing relevant computational methods that can be applied to the problem of

improving the quality of life.

9. Maurer, RI; Blower, PJ; Dilworth, JR; Reynolds, CA; Zheng, YF; Mullen, GED

Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone)

radiopharmaceuticals. J. Med. Chem. 2002, 45, 1420-1431.

10. Congreve, M; Chessari, G; Tisi, D; Woodhead, AJ. Recent developments in

fragment-based drug discovery. J. Med. Chem 2008, 51, 3661-3680.

5

11. Misquitta, AJ; Welch, GWA; Stone, AJ; Price, S. L. A first principles prediction of

the crystal structure of C6Br2ClFH2. Chem. Phys. Lett. 2008, 456, 105-109.

12. Jorgensen, WL Special issue on polarization. J. Chem. Theory Comput. 2007, 3,

1877.

13. Mura, ME; Knowles, PJ; Reynolds, CA Accurate numerical determination of Kohn-

Sham potentials from electronic densities .1. Two-electron systems. J. Chem. Phys.

1997, 106, 9659-9667.</gtr:technicalSummary><gtr:fund><gtr:end>2014-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>78798</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Reading</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy Reading</gtr:department><gtr:description>CGRP antagonists</gtr:description><gtr:id>4C3BAE0F-46F1-42A1-85EB-5459DEA09E66</gtr:id><gtr:impact>This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.</gtr:impact><gtr:outcomeId>54620bbe5b5318.65983043-4</gtr:outcomeId><gtr:partnerContribution>Pharmonovo supply ligands and coordinate the project
David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology.
OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry
University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling
University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor.
University of Essex, Mike Hough, X-ray crystallography
Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action.
PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty &amp;amp; Szentagothai Research Center of the University of P&amp;eacute;cs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.</gtr:partnerContribution><gtr:piContribution>Modelling interactions of ligands with the CGRP receptor and other proteins.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CGRP collaboration</gtr:description><gtr:id>F9637C60-6E26-40D2-961B-574180984821</gtr:id><gtr:impact>Multi-disciplinary: (i) cell-biology/pharmacology (ii) computational chemistry / structural bioinformatics
PMID: 24047872
PMID: 23356280
PMID: 23235263</gtr:impact><gtr:outcomeId>nx23jUKK3HY-4</gtr:outcomeId><gtr:partnerContribution>Experimental site-directed mutagenesis, cell biology, pharmacology</gtr:partnerContribution><gtr:piContribution>Bioinformatics, Docking, Comparative Modelling, Molecular Modelling, Molecular Dynamics simulation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aston University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CGRP antagonists</gtr:description><gtr:id>1EFCFE5D-7A1A-4F6B-A50A-2684C0943C2C</gtr:id><gtr:impact>This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.</gtr:impact><gtr:outcomeId>54620bbe5b5318.65983043-2</gtr:outcomeId><gtr:partnerContribution>Pharmonovo supply ligands and coordinate the project
David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology.
OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry
University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling
University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor.
University of Essex, Mike Hough, X-ray crystallography
Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action.
PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty &amp;amp; Szentagothai Research Center of the University of P&amp;eacute;cs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.</gtr:partnerContribution><gtr:piContribution>Modelling interactions of ligands with the CGRP receptor and other proteins.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pecs</gtr:collaboratingOrganisation><gtr:department>Department of Pharmacology and Pharmacotherapy</gtr:department><gtr:description>CGRP antagonists</gtr:description><gtr:id>E6F4CFC6-6DB0-4ED8-B775-F7B2C6FCA602</gtr:id><gtr:impact>This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.</gtr:impact><gtr:outcomeId>54620bbe5b5318.65983043-6</gtr:outcomeId><gtr:partnerContribution>Pharmonovo supply ligands and coordinate the project
David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology.
OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry
University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling
University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor.
University of Essex, Mike Hough, X-ray crystallography
Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action.
PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty &amp;amp; Szentagothai Research Center of the University of P&amp;eacute;cs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.</gtr:partnerContribution><gtr:piContribution>Modelling interactions of ligands with the CGRP receptor and other proteins.</gtr:piContribution><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aston University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Glucagon and GLP-1 receptor</gtr:description><gtr:id>9CBF450B-9DD1-4C94-BF95-D74184430E86</gtr:id><gtr:impact>multi-disciplinary: (i) cell biology (Warwick), (ii) pharmacology (Aston), (iii) computational chemistry (comparative modelling, docking, Essex)
Publication in preparation, entitled 'Modulation of glucagon receptor pharmacology by RAMP2', by Weston, C., Lu, J., Richards, G. O., Roberts, D. J., Skerry, T. M., Dowell, S. J., Willars, G. B., Reynolds C.A. and Ladds, G. 
Grant Application on biased signalling in the GLP-1 receptor in preparation (with G. Ladds, D.R. Poyner).</gtr:impact><gtr:outcomeId>54620d17e49365.01912468-2</gtr:outcomeId><gtr:partnerContribution>Yeast Cell Biology (Ladds, Warwick until mid 2015; now Cambridge); Pharmacology (Poyner, Aston)</gtr:partnerContribution><gtr:piContribution>Molecular modelling: interactions between peptide ligand and receptor</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CGRP collaboration</gtr:description><gtr:id>3F61C428-723F-42A1-921C-81CC4A92B185</gtr:id><gtr:impact>Multi-disciplinary: (i) cell-biology/pharmacology (ii) computational chemistry / structural bioinformatics
PMID: 24047872
PMID: 23356280
PMID: 23235263</gtr:impact><gtr:outcomeId>nx23jUKK3HY-2</gtr:outcomeId><gtr:partnerContribution>Experimental site-directed mutagenesis, cell biology, pharmacology</gtr:partnerContribution><gtr:piContribution>Bioinformatics, Docking, Comparative Modelling, Molecular Modelling, Molecular Dynamics simulation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Closed Loops</gtr:description><gtr:id>E010B069-E058-49A5-96FC-0399736D5AA8</gtr:id><gtr:impact>Chintapalli, S. V.; Illingworth, C. J.; Upton, G. J.; Sacquin-Mora, S.; Reeves, P. J.; Mohammedali, H. S.; Reynolds, C. A. Assessing the effect of dynamics on the closed-loop protein-folding hypothesis. J R. Soc Interface 2014, 11 (91), 20130935. PMID: 24258160, doi: 10.1098/rsif.2013.0935</gtr:impact><gtr:outcomeId>mTRGj94L1MR-1</gtr:outcomeId><gtr:partnerContribution>coarse-grain elastic network simulations</gtr:partnerContribution><gtr:piContribution>Protein modelling, statistics</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Monash University</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Biased signalling in the GLP1 receptor</gtr:description><gtr:id>2803BB95-039D-48AA-8314-6274AF97BBA9</gtr:id><gtr:impact>Wootten, D.; Reynolds, C. A.; Koole, C.; Smith, K. J.; Mobarec, J. C.; Quon, T.; Coudrat, T.; Furness, S. G. B.; Miller, L. J.; Christopoulos, A.; Sexton, P. M. A hydrogen-bonded polar network in the core of the glucagon-like peptide-1 receptor is a fulcrum for biased agonism: lessons from class B crystal structures. Mol. Pharmacol. (resubmitted) 2016, 89, 335-347</gtr:impact><gtr:outcomeId>56d84939a12639.39166109-1</gtr:outcomeId><gtr:partnerContribution>Experimental mutagenesis studies of the GLP1 receptor and an analysis of the preferred signalling pathways of the receptor in the presence of various agonists, namely GLP1 peptide, oxyntmodulin and exendin-4</gtr:partnerContribution><gtr:piContribution>homology Modelling the GLP1 receptor; molecular dynamics studies of the GLP1 receptor; docking studies on ligands binding to the receptor</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pharmnovo AB/Pharmnovo UK Ltd</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>CGRP antagonists</gtr:description><gtr:id>76A41513-DF48-4DB0-85BC-25E322569C36</gtr:id><gtr:impact>This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.</gtr:impact><gtr:outcomeId>54620bbe5b5318.65983043-1</gtr:outcomeId><gtr:partnerContribution>Pharmonovo supply ligands and coordinate the project
David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology.
OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry
University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling
University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor.
University of Essex, Mike Hough, X-ray crystallography
Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action.
PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty &amp;amp; Szentagothai Research Center of the University of P&amp;eacute;cs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.</gtr:partnerContribution><gtr:piContribution>Modelling interactions of ligands with the CGRP receptor and other proteins.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aston University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CGRP collaboration</gtr:description><gtr:id>DC15FD48-FF99-4190-8839-C5AC8312540E</gtr:id><gtr:impact>Multi-disciplinary: (i) cell-biology/pharmacology (ii) computational chemistry / structural bioinformatics
PMID: 24047872
PMID: 23356280
PMID: 23235263</gtr:impact><gtr:outcomeId>nx23jUKK3HY-1</gtr:outcomeId><gtr:partnerContribution>Experimental site-directed mutagenesis, cell biology, pharmacology</gtr:partnerContribution><gtr:piContribution>Bioinformatics, Docking, Comparative Modelling, Molecular Modelling, Molecular Dynamics simulation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of South Bohemia</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>Modelling polarization</gtr:description><gtr:id>DF1D9F13-13D9-45DB-8D57-2C2A93005FDE</gtr:id><gtr:impact>Polarized docking software</gtr:impact><gtr:outcomeId>5463c983489183.28221847-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input, computing resources and programming skills, with an emphasis on quantum chemistry and programing.</gtr:partnerContribution><gtr:piContribution>Intellectual input, computing resources and programming skills</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Warwick Medical School</gtr:department><gtr:description>Yeast Pheramone Receptors: similarity to mamalian GPCRs</gtr:description><gtr:id>A119E09A-D57B-4FDF-B06D-F889D34BFA74</gtr:id><gtr:impact>Multi-disciplinary: (i) cell biology, (ii) computational chemistry/ docking /structural bioinformatics.
A draft manuscript is in preparation entitled: 'Towards a molecular level understanding of yeast pheromone receptors' by Graham Ladds, Graham J.G. Upton, Hugh R. Allen, Asil M. Amin, Liam Davidson-Gates, Jack Sawyer, Sophie Smith, and Christopher A Reynolds</gtr:impact><gtr:outcomeId>546211884863f9.38813170-1</gtr:outcomeId><gtr:partnerContribution>Cell Biology, random and site-directed mutagenesis, pharmacology</gtr:partnerContribution><gtr:piContribution>Molecular Modelling receptor structure based on a novel approach to aligning sequences in or below the twilight zone; docking peptide ligands to the receptor</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mayo Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Molecular Pharmacology and Experimental Therapeutics</gtr:department><gtr:description>Biased signalling in the GLP1 receptor</gtr:description><gtr:id>94F6F0A8-C14D-4C49-B3E9-A852E70D76B2</gtr:id><gtr:impact>Wootten, D.; Reynolds, C. A.; Koole, C.; Smith, K. J.; Mobarec, J. C.; Quon, T.; Coudrat, T.; Furness, S. G. B.; Miller, L. J.; Christopoulos, A.; Sexton, P. M. A hydrogen-bonded polar network in the core of the glucagon-like peptide-1 receptor is a fulcrum for biased agonism: lessons from class B crystal structures. Mol. Pharmacol. (resubmitted) 2016, 89, 335-347</gtr:impact><gtr:outcomeId>56d84939a12639.39166109-2</gtr:outcomeId><gtr:partnerContribution>Experimental mutagenesis studies of the GLP1 receptor and an analysis of the preferred signalling pathways of the receptor in the presence of various agonists, namely GLP1 peptide, oxyntmodulin and exendin-4</gtr:partnerContribution><gtr:piContribution>homology Modelling the GLP1 receptor; molecular dynamics studies of the GLP1 receptor; docking studies on ligands binding to the receptor</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>OnTarget Chemistry</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>CGRP antagonists</gtr:description><gtr:id>B9F8F279-FD19-4849-A8A2-6DF96024376E</gtr:id><gtr:impact>This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.</gtr:impact><gtr:outcomeId>54620bbe5b5318.65983043-7</gtr:outcomeId><gtr:partnerContribution>Pharmonovo supply ligands and coordinate the project
David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology.
OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry
University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling
University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor.
University of Essex, Mike Hough, X-ray crystallography
Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action.
PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty &amp;amp; Szentagothai Research Center of the University of P&amp;eacute;cs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.</gtr:partnerContribution><gtr:piContribution>Modelling interactions of ligands with the CGRP receptor and other proteins.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Auckland</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:description>CGRP collaboration</gtr:description><gtr:id>D6A04837-DE00-4983-A880-C29AC53A4CC5</gtr:id><gtr:impact>Multi-disciplinary: (i) cell-biology/pharmacology (ii) computational chemistry / structural bioinformatics
PMID: 24047872
PMID: 23356280
PMID: 23235263</gtr:impact><gtr:outcomeId>nx23jUKK3HY-3</gtr:outcomeId><gtr:partnerContribution>Experimental site-directed mutagenesis, cell biology, pharmacology</gtr:partnerContribution><gtr:piContribution>Bioinformatics, Docking, Comparative Modelling, Molecular Modelling, Molecular Dynamics simulation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biomedical Sciences Nottingham</gtr:department><gtr:description>CGRP antagonists</gtr:description><gtr:id>1C9FD48E-88B9-4155-B2AE-D79F1C340998</gtr:id><gtr:impact>This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.</gtr:impact><gtr:outcomeId>54620bbe5b5318.65983043-3</gtr:outcomeId><gtr:partnerContribution>Pharmonovo supply ligands and coordinate the project
David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology.
OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry
University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling
University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor.
University of Essex, Mike Hough, X-ray crystallography
Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action.
PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty &amp;amp; Szentagothai Research Center of the University of P&amp;eacute;cs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.</gtr:partnerContribution><gtr:piContribution>Modelling interactions of ligands with the CGRP receptor and other proteins.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Warwick Medical School</gtr:department><gtr:description>Glucagon and GLP-1 receptor</gtr:description><gtr:id>C22BEB33-62F2-4050-B43D-A2D5948BEBD0</gtr:id><gtr:impact>multi-disciplinary: (i) cell biology (Warwick), (ii) pharmacology (Aston), (iii) computational chemistry (comparative modelling, docking, Essex)
Publication in preparation, entitled 'Modulation of glucagon receptor pharmacology by RAMP2', by Weston, C., Lu, J., Richards, G. O., Roberts, D. J., Skerry, T. M., Dowell, S. J., Willars, G. B., Reynolds C.A. and Ladds, G. 
Grant Application on biased signalling in the GLP-1 receptor in preparation (with G. Ladds, D.R. Poyner).</gtr:impact><gtr:outcomeId>54620d17e49365.01912468-1</gtr:outcomeId><gtr:partnerContribution>Yeast Cell Biology (Ladds, Warwick until mid 2015; now Cambridge); Pharmacology (Poyner, Aston)</gtr:partnerContribution><gtr:piContribution>Molecular modelling: interactions between peptide ligand and receptor</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Glucagon and GLP-1 receptor</gtr:description><gtr:id>622551DD-72C1-4945-ADCD-EB77B8D1A34D</gtr:id><gtr:impact>multi-disciplinary: (i) cell biology (Warwick), (ii) pharmacology (Aston), (iii) computational chemistry (comparative modelling, docking, Essex)
Publication in preparation, entitled 'Modulation of glucagon receptor pharmacology by RAMP2', by Weston, C., Lu, J., Richards, G. O., Roberts, D. J., Skerry, T. M., Dowell, S. J., Willars, G. B., Reynolds C.A. and Ladds, G. 
Grant Application on biased signalling in the GLP-1 receptor in preparation (with G. Ladds, D.R. Poyner).</gtr:impact><gtr:outcomeId>54620d17e49365.01912468-3</gtr:outcomeId><gtr:partnerContribution>Yeast Cell Biology (Ladds, Warwick until mid 2015; now Cambridge); Pharmacology (Poyner, Aston)</gtr:partnerContribution><gtr:piContribution>Molecular modelling: interactions between peptide ligand and receptor</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Discovery Partnerships with Academia</gtr:department><gtr:description>Industry Interchange</gtr:description><gtr:id>9B86F799-7732-48C5-957D-C0896DC0F47F</gtr:id><gtr:impact>See publications involving Ian Wall</gtr:impact><gtr:outcomeId>mkNUmwu6fFX-1</gtr:outcomeId><gtr:partnerContribution>Advice in how to apply these methods to FBDD</gtr:partnerContribution><gtr:piContribution>Novel QM/MM methods that include a polarizable MM region for application to fragment-based drug design (FBDD)</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CGRP antagonists</gtr:description><gtr:id>179ABA6E-6234-40CB-941A-6D39077F4960</gtr:id><gtr:impact>This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.</gtr:impact><gtr:outcomeId>54620bbe5b5318.65983043-5</gtr:outcomeId><gtr:partnerContribution>Pharmonovo supply ligands and coordinate the project
David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology.
OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry
University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling
University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor.
University of Essex, Mike Hough, X-ray crystallography
Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action.
PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty &amp;amp; Szentagothai Research Center of the University of P&amp;eacute;cs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.</gtr:partnerContribution><gtr:piContribution>Modelling interactions of ligands with the CGRP receptor and other proteins.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Drug Design Workshop for the giften and able</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5127F4E9-D975-4B58-B3BD-6324972E6245</gtr:id><gtr:impact>8 Gifted and able students from Bromfords School, Essex, attended a week-long drug design workshop, which greatly increased the pupils enthusiasm for science.</gtr:impact><gtr:outcomeId>58c18e53ae4e78.64454467</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>HPC Europa2 transnational visit: Taddese</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>A2CDFD2A-0220-49AC-881F-EE749E33297B</gtr:id><gtr:outcomeId>T8yX1QKNAAM</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Responsive mode</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>Email from BBSRC to say that the grant will be announced in due course</gtr:fundingRef><gtr:id>B9A6C0A0-D7AA-47EB-9BEF-CFD5DA16F444</gtr:id><gtr:outcomeId>54621730948ac6.71902777</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>74285</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pancreatic cancer UK</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Pancreatic Cancer UK</gtr:fundingOrg><gtr:fundingRef>A11</gtr:fundingRef><gtr:id>A6D95130-E91F-4D84-AA60-58B33BC5E10D</gtr:id><gtr:outcomeId>58c18aac25d5f1.74758891</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>HPC-Europa2 transnational visit: Reynolds</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>0D2A5D41-047B-4587-BF25-1D892D445211</gtr:id><gtr:outcomeId>XSN3Jg1zUsr</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Software for aligning remote homologues, i.e. the software can, in favourabel circumstances, be used to align profiles where the mean percentage identity is below the 18-25% that makes alignment almost impossible.</gtr:description><gtr:id>26A8BCC9-6A1A-4720-8048-DA1A48AA321A</gtr:id><gtr:impact>The software has been used to align GCR1 homologues to class A, class B and class F GPCRs and hence show that plants contain GPCRs - or at least that they contain GPCR motifs, as shown in Taddese et al., PlantPhys, 2014, PMID 24246381. The software can also be used to align and hence dock pharmaceutically important peptide ligands, as will be shown in Weaver et al., in preparation (collaboration with D. Donnelly) and Weston et al., (collaboration with G. Ladds). Resources will be sought, e.g. from BBSRC, to enhance this software and to make it available as a web server.</gtr:impact><gtr:outcomeId>5462447509eb95.56563051</gtr:outcomeId><gtr:title>Sequence alignment software</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>The search for a new drug may start on the computer by 'docking' potential molecules into a structure of the drug target, which is typically an enzyme or a receptor. Molecules that are calculated to fit well can therefore be made and tested experimentally, while those calculated to have a poor fit can be ignored, thus saving time and expense. However, these calculations do not always work well. These calculations usually assumes that the atomic charge distribution on the molecule and the enzyme does not change when the molecule approaches the enzyme even when the charges on some of the atoms are quite high and might therefore affect each other, i.e. one molecule might polarize the other. We have developed a method of including enzyme polarization and ligand polarization in docking that can be combined with standard state-of-the art docking software, e.g. Glide. This should greatly reduce one of the main errors in docking. The method is based on a series of Perl scripts and converts an induced dipole to a set of induced charges. The induced dipole can be calculated classically, or quantum mechanically. Typically the induced dpole at the enzyme is calculated from the ligand quantum mechanical electrostatic potential at the atoms of the enzyme.</gtr:description><gtr:id>A9888808-E2EC-497F-85F5-3A989625C38B</gtr:id><gtr:impact>Inclusion of polarization by this method typically halves the proportion of compounds incorrectly docked using GLIDE, a state-of the art docking program and therefore has the potential to facilitate the drug design process. This is particularly true when appropriate water molecules are included as part of the enzyme target.</gtr:impact><gtr:outcomeId>5462391323a196.22087688</gtr:outcomeId><gtr:title>polarization software</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://ftp://ftp.essex.ac.uk/pub/oyster/polarization</gtr:url><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>666DEB55-490E-44C5-9A5B-AF63E4291E38</gtr:id><gtr:title>Assessing the effect of dynamics on the closed-loop protein-folding hypothesis.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society, Interface</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfac3c714f3f4d033fce695cc1880d34"><gtr:id>cfac3c714f3f4d033fce695cc1880d34</gtr:id><gtr:otherNames>Chintapalli SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-5662</gtr:issn><gtr:outcomeId>asvNRgfis1z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B3F1BC8-FDCB-4BB3-8FDB-C6274F0D7CB0</gtr:id><gtr:title>Identifying subset errors in multiple sequence alignments.</gtr:title><gtr:parentPublicationTitle>Journal of biomolecular structure &amp; dynamics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4f5d0920d73a0a7caca3b42bf26d5a4"><gtr:id>f4f5d0920d73a0a7caca3b42bf26d5a4</gtr:id><gtr:otherNames>Roy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0739-1102</gtr:issn><gtr:outcomeId>sMwF9Awsq2c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F54CD33C-D6F1-426A-BF98-71C72A2B373D</gtr:id><gtr:title>Similarity between class A and class B G-protein-coupled receptors exemplified through calcitonin gene-related peptide receptor modelling and mutagenesis studies.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society, Interface</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1ceeb6c7a60eb2c44c6e57e70e1a839"><gtr:id>a1ceeb6c7a60eb2c44c6e57e70e1a839</gtr:id><gtr:otherNames>Vohra S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-5662</gtr:issn><gtr:outcomeId>pm_15406_26_23235263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC345184-C0AA-46D3-8903-93D765DB03DD</gtr:id><gtr:title>The role of ECL2 in CGRP receptor activation: a combined modelling and experimental approach.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society, Interface</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b36746b46b4f13291f1db8640097ffc"><gtr:id>2b36746b46b4f13291f1db8640097ffc</gtr:id><gtr:otherNames>Woolley MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-5662</gtr:issn><gtr:outcomeId>pm_15406_26_24047872</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCBFA6B8-2650-41C7-9CA8-DFF07D14D865</gtr:id><gtr:title>The statistical significance of selected sense-antisense peptide interactions.</gtr:title><gtr:parentPublicationTitle>Journal of computational chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a47cf77cca5ec8bdb50fda038047e23"><gtr:id>9a47cf77cca5ec8bdb50fda038047e23</gtr:id><gtr:otherNames>Illingworth CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0192-8651</gtr:issn><gtr:outcomeId>AsdTWWuJ8Xn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8893F9B7-E4E0-44A4-A4F6-7233F2D5C070</gtr:id><gtr:title>Key interactions by conserved polar amino acids located at the transmembrane helical boundaries in Class B GPCRs modulate activation, effector specificity and biased signalling in the glucagon-like peptide-1 receptor.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcfd17610c8427e8890582a3b5003190"><gtr:id>bcfd17610c8427e8890582a3b5003190</gtr:id><gtr:otherNames>Wootten D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>585d3383d30eb5.45262374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62744A13-9C24-47E8-9CE0-79B92536A3E8</gtr:id><gtr:title>A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcfd17610c8427e8890582a3b5003190"><gtr:id>bcfd17610c8427e8890582a3b5003190</gtr:id><gtr:otherNames>Wootten D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>56d846674c7a73.05552028</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>543D6CF9-44F3-46B9-87FF-FFCE5EF0768E</gtr:id><gtr:title>Modeling active GPCR conformations.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a81ef4c98d4f45274ecdd656d9138924"><gtr:id>a81ef4c98d4f45274ecdd656d9138924</gtr:id><gtr:otherNames>Taddese B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0076-6879</gtr:issn><gtr:outcomeId>caREyuxV9St</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E67A698-CFB0-479D-96A3-CE54A89D7F63</gtr:id><gtr:title>Do plants contain g protein-coupled receptors?</gtr:title><gtr:parentPublicationTitle>Plant physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a81ef4c98d4f45274ecdd656d9138924"><gtr:id>a81ef4c98d4f45274ecdd656d9138924</gtr:id><gtr:otherNames>Taddese B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0032-0889</gtr:issn><gtr:outcomeId>54622d9dea5a95.23550847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F10E5CEC-5FF5-46F1-A078-CB5834FEF2F1</gtr:id><gtr:title>The activation of the CGRP receptor.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea02cf7e8d3ef4a7ec95df0dcfc01a3"><gtr:id>2ea02cf7e8d3ef4a7ec95df0dcfc01a3</gtr:id><gtr:otherNames>Barwell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_15406_26_23356280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC9551B3-5376-4EFC-B8F1-212194863A38</gtr:id><gtr:title>G-protein-coupled receptor dynamics: dimerization and activation models compared with experiment.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a81ef4c98d4f45274ecdd656d9138924"><gtr:id>a81ef4c98d4f45274ecdd656d9138924</gtr:id><gtr:otherNames>Taddese B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_15406_26_22435818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6B5BA35-7E7E-4A09-8776-6096925D1E31</gtr:id><gtr:title>The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcfd17610c8427e8890582a3b5003190"><gtr:id>bcfd17610c8427e8890582a3b5003190</gtr:id><gtr:otherNames>Wootten D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>57922cce7659f6.11713282</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001812</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>